AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02551536
Drug: Levocetrizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
Trial: NCT03443141
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The applied dressing is a normal one without adding any product to it.
Trial: NCT02017197
Drug: Marevan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
Trial: NCT00979901
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet given once daily at bedtime for 2 weeks
Trial: NCT01702974
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
Trial: NCT02228707
Drug: BIIB061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive BIIB061
Trial: NCT01576887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT01005251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral,capsules, bid for 4 w
Trial: NCT00810849
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
Trial: NCT01117428
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.
Trial: NCT02538458
Drug: 3 % hypertonic saline up to 72H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
Trial: NCT02538458
Drug: 3 % hypertonic saline up to 24H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group.
Trial: NCT04236440
Drug: Placebo (A2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BAY2586116 (nasal spray administration)
Trial: NCT04236440
Drug: BAY2586116 (B1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg BAY2586116 (nasal drops)
Trial: NCT04236440
Drug: BAY2586116 (B3)
RxNorm normalized name: VITAMIN B3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
Trial: NCT02798367
Drug: CBT-I plus Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Trial: NCT02798367
Drug: CBT-I plus Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Trial: NCT02061540
Drug: LUM001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM001 oral dose
Trial: NCT01804413
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1-0.15 units/kg
Trial: NCT02543801
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Trial: NCT02543801
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Trial: NCT01227252
Drug: LY2886721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
Trial: NCT01227252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules, daily for 14 days
Trial: NCT00346216
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 to 200 mg twice daily, taken by mouth
Trial: NCT00346216
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 600 mg to 800 mg three times daily, taken by mouth
Trial: NCT01608555
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: inhaled tobramycin 300 mg single dose OD for 28 days
Trial: NCT00346216
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 375mg to 500 mg twice daily, taken by mouth
Trial: NCT02499159
Drug: 0.25% standard bupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
Trial: NCT00597857
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
Trial: NCT00597857
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receipt of a placebo pill for 16 days
Trial: NCT00819091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1356 5mg one tablet daily
Trial: NCT00972075
Drug: melatonin (Circadin)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
Trial: NCT00972075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet per day 2 hours before going to bed
Trial: NCT03977792
Drug: BOR15001L7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
Trial: NCT02097394
Drug: Combizym
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combizym( 1 tablet, po, tid)
Trial: NCT00141453
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT02252042
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
Trial: NCT02355925
Drug: intrauterine injection of uhCG
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
Trial: NCT02355925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
Trial: NCT02404038
Drug: Nur-Isterate
RxNorm normalized name: Glyceryl Distearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
Trial: NCT02818309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02345174
Drug: GSK2849330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
Trial: NCT01725906
Drug: empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
Trial: NCT01725906
Drug: Genotypic resistance guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
Trial: NCT00400777
Drug: Valsartan, hydrochlorothiazide and amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00391898
Drug: Levodopa/carbidopa/entacapone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
Trial: NCT00391898
Drug: Levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
Trial: NCT02404038
Drug: Triphasil
RxNorm normalized name: Triphasil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert
Trial: NCT01711333
Drug: Pletaal SR capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two capsules once a day of Pletaal SR 100mg Capsules
Trial: NCT04207944
Drug: Sulindac 400 MG
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
Trial: NCT03710291
Drug: TRC101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, non-absorbed, polymeric hydrochloric acid binder
Trial: NCT03710291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01766401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766401
Drug: Vilazadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viibryd
Trial: NCT01020994
Drug: LAS41003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT01020994
Drug: LAS189962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT01020994
Drug: LAS189961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT04430036
Drug: AGEN1884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fully human monoclonal Anti-PD-1 Antibody
Trial: NCT04430036
Drug: AGEN2034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fully human monoclonal Anti-PD-1 Antibody
Trial: NCT00642824
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
Trial: NCT01614951
Drug: HTK Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmoplegia before ECC.
Trial: NCT02755259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02442765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06178835
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Trial: NCT00003958
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05536934
Drug: Nω-hydroxy-nor-arginine
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910104
Drug: Omegaven®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
Trial: NCT02546999
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The agent will be given only once at point zero in the time scheme for the project.
Trial: NCT00755521
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg
Trial: NCT04971759
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levobupivacaine 5% + 1µg/kg fentanyl
Trial: NCT01984294
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
Trial: NCT04335357
Drug: TBR-760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
Trial: NCT04335357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02376790
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
Trial: NCT02376790
Drug: Placebo to Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to methotrexate capsules taken orally once a week.
Trial: NCT02542657
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00044564
Drug: Bay 59-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Trial: NCT02641938
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
Trial: NCT03995147
Drug: R-CHOP Protocol
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
Trial: NCT03562884
Drug: BLI800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
Trial: NCT03643900
Drug: rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rectal indomethacin 100mg at preoperative 30min
Trial: NCT02407808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Trial: NCT02182336
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: days 1, 10 and 19
Trial: NCT00004257
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02238483
Drug: AZD7624 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled AZD7624 solution, 11 mg/mL
Trial: NCT02238483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo solution
Trial: NCT03392896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
Trial: NCT02574455
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
Trial: NCT00099801
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01389895
Drug: AMG 557 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Trial: NCT02965846
Drug: AGN-195263
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.
Trial: NCT02965846
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
Trial: NCT00606021
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Trial: NCT02058875
Drug: Myfortic®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02058875
Drug: Neoral®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02058875
Drug: Cellcept®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02777008
Drug: Placebo for CTP-543
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03152175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg / kg of matched placebo, oral capsule
Trial: NCT02067104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Trial: NCT00677391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, once daily
Trial: NCT00462358
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Trial: NCT01594489
Drug: Hydration plus N-acetylcisteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI
Trial: NCT01431794
Drug: LDE225-600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
Trial: NCT01431794
Drug: LDE225-400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.
Trial: NCT01431794
Drug: LDE225-800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.